Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8718720 | 0.86 | CA2 (0.32) | CA2CA1CA12CA7CA14 | |
| SCHEMBL15215211 | 0.84 | CA2 (0.40) | CA2CA1CA12CA7CA14 | |
| SCHEMBL1425858 | 0.79 | CA2 (0.35) | CA2TSHRTDP1 | |
| SCHEMBL15773891 | 0.79 | — | — | |
| SCHEMBL13997140 | 0.77 | — | — | |
| SCHEMBL13254849 | 0.77 | — | — | |
| SCHEMBL25235825 | 0.77 | — | — | |
| SCHEMBL9651396 | 0.77 | CA2 (0.56) | CA2CA1TSHRTDP1CA9 | |
| SCHEMBL4667979 | 0.77 | — | — | |
| SCHEMBL8329628 | 0.77 | CA2 (0.33) | CA2CA1CA7TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1064013-A4 | $i(IN VITRO) FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | UNIV WASHINGTON (US) | 2005-05-11 | — | — | EP | claimed |
| EP-1064013-A1 | $i(IN VITRO) FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | University of Washington (US) | 2001-01-03 | — | — | EP | claimed |
| WO-1999045947-A9 | IN VITRO FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | UNIV WASHINGTON (US) | 2000-03-02 | — | — | WO | claimed |
| WO-1999045947-A1 | IN VITRO FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | UNIVERSITY OF WASHINGTON (US) | 1999-09-16 | — | — | WO | claimed |
| US-20140155480-A1 | Scyllo-Inositol Derivatives and Their Use in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation of Amyloid Formation, Deposition, Accumulation for Persistence | WARATAH PHARMACEUTICALS INC. (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20140135403-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF OCULAR DISEASES | WARATAH PHARMACEUTICALS INC. (CA) | 2014-05-15 | — | — | US | disclosed |
| EP-2656839-A1 | Use of Cyclohexanehexol Derivatives in the Treatment of Ocular Diseases | Waratah Pharmaceuticals, Inc. (CA) | 2013-10-30 | — | — | EP | disclosed |
| US-20110105626-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | MCLAURIN JOANNE | 2011-05-05 | — | — | US | disclosed |
| US-20100331267-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF ALPHA-SYNUCLEINOPATHIES | MCLAURIN JOANNE | 2010-12-30 | — | — | US | disclosed |
| US-20100292157-A1 | Combination Treatments for Alzheimer's Disease and Similar Diseases | WARATAH PHARMACEUTICALS INC. (CA) | 2010-11-18 | — | — | US | disclosed |
| US-20100173960-A1 | The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases | WARATAH PHARMACEUTICALS INC. (CA) | 2010-07-08 | — | — | US | disclosed |
| US-20100168250-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF OCULAR DISEASE | WARATAH PHARMACEUTICALS INC. (CA) | 2010-07-01 | — | — | US | disclosed |
| US-7148001-B2 | In vitro formation of congophilic maltese-cross amyloid plaques to identify anti-plaque therapeutics for the treatment of Alzheimer's and Prion diseases | UNIVERSITY OF WASHINGTON (US) | 2006-12-12 | — | — | US | disclosed |
| EP-1064013-A4 | $i(IN VITRO) FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | UNIV WASHINGTON (US) | 2005-05-11 | — | — | EP | disclosed |
| US-20020168753-A1 | In vitro formation of congophilic maltese-cross amyloid plaques to identify anti-plaque therapeutics for the treatment of Alzheimer's and Prion diseases | NATIONAL INSTITUTES OF HEALTH | 2002-11-14 | — | — | US | disclosed |
| EP-1064013-A1 | $i(IN VITRO) FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | University of Washington (US) | 2001-01-03 | — | — | EP | disclosed |
| EP-1054664-A1 | METHOD FOR MODULATING MACROPHAGE ACTIVATION | Neurochem, Inc. (CA) | 2000-11-29 | — | — | EP | disclosed |
| WO-1999045947-A9 | IN VITRO FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | UNIV WASHINGTON (US) | 2000-03-02 | — | — | WO | disclosed |
| WO-1999045947-A1 | IN VITRO FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | UNIVERSITY OF WASHINGTON (US) | 1999-09-16 | — | — | WO | disclosed |
| WO-1999040909-A1 | METHOD FOR MODULATING MACROPHAGE ACTIVATION | NEUROCHEM, INC. (CA) | 1999-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331267-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF ALPHA-SYNUCLEINOPATHIES | SNCA, PARK7, PMP22 | CA2 2600/4885CA1 2680/4885CA12 3894/4885 |
| US-20110105626-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | CDR2, HYPK, HTT | CA2 4000/4885CA1 4311/4885CA12 4729/4885 |
| US-20100168250-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF OCULAR DISEASE | APP, IAPP, TTR | CA2 1036/4885CA1 1492/4885CA12 1079/4885 |
| US-20100292157-A1 | Combination Treatments for Alzheimer's Disease and Similar Diseases | APP, PSEN1, BACE1 | CA2 1837/4885CA1 699/4885CA12 2973/4885 |
| US-20100173960-A1 | The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases | HTT, APP, PSEN2 | CA2 1438/4885CA1 1175/4885CA12 3183/4885 |
| US-20140135403-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF OCULAR DISEASES | APP, IAPP, TTR | CA2 1094/4885CA1 1602/4885CA12 1107/4885 |
| US-20140155480-A1 | Scyllo-Inositol Derivatives and Their Use in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation of Amyloid Formation, Deposition, Accumulation for Persistence | SCLY, SCO2, SGMS2 | CA2 2349/4885CA1 3722/4885CA12 4254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.